



# STIC Search Report

## Biotech-Chem Library

STIC Database Tracking Number: 107433

TO: Janet Epps  
Location: cm1/11e01/11e12  
Art Unit: 1635  
Monday, November 10, 2003  
Case Serial Number: 09/817387

From: Paul Schulwitz  
Location: Biotech-Chem Library  
CM1-6B06  
Phone: 305-1954

[paul.schulwitz@uspto.gov](mailto:paul.schulwitz@uspto.gov)

### Search Notes

Examiner Epps,

See attached results.

If you have any questions about this search feel free to contact me at any time.

Thank you for using STIC search services!

Paul Schulwitz  
Technical Information Specialist  
STIC Biotech/Chem Library  
(703)305-1954



Pending Nucleic Acid and/or Pending Amino Acid database searches now generate two sets of results. These databases were split into two parts to reduce the time needed to update the databases daily. The split freed up more machine time for processing searches.

Searches run against the Nucleic Acid Pending database produce two sets of results, with the extensions, **.rnpm** and **.rnpn**

Searches run against the Amino Acid Pending database produce two sets of results, with the extensions, **.rapm** and **.rapn**

*The Pending database search results should not be left in the case because they contain data that is confidential.*

```
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
; TITLE OF INVENTION: THAT POPULATE A TRANSCRIPTONE
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975
; PRIOR FILING DATE: 2001-07-20
; PRIOR APPLICATION NUMBER: US 60/287,724
; PRIOR FILING DATE: 2001-05-02
; PRIOR APPLICATION NUMBER: US 60/221,607
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 32337
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 29537
; LENGTH: 65
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-908-975-29537

Query Match      72.2%; Score 16.6; DB 12; Length 65;
Best Local Similarity 69.6%; Pred. No. 1.6e+02;
Matches 16; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY      1 GTACTGCTCAGAGUAGGUUAG 23
        |||||:||||:||||:
DB      47 GTAGTCTCAGAGTTGGGGTAG 25

RESULT 15
US-09-817-387-2
; Sequence 2, Application US/09817387
; Patent No. US20010039263A1
; GENERAL INFORMATION:
; APPLICANT: Max-Delbruck-Centrum fur Molekulare Medizin
; TITLE OF INVENTION: Chimeric Oligonucleotides and the Use Thereof
; FILE REFERENCE: 101195-24
; CURRENT APPLICATION NUMBER: US/09/817,387
; CURRENT FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: DE 197 20 151.2
; PRIOR FILING DATE: 1997-05-02
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: oligonucleotide linkages between positions 1 to
; OTHER INFORMATION: 20 are phosphorothioates, linkages between
; OTHER INFORMATION: positions 20 to 25 are phosphodiester
US-09-817-387-2

Query Match      67.0%; Score 15.4; DB 9; Length 25;
Best Local Similarity 82.4%; Pred. No. 5.9e+02;
Matches 14; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY      1 GTACTGCTCAGAGUAG 17
        |||||:||||:||||:
DB      9  GGACTGCTCAGAGTTAG 25

Search completed: November 8, 2003, 04:56:13
Job time : 172 secs
```

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2003, 04:01:47 ; Search time 170 Seconds  
(without alignments)  
365.218 Million cell updates/sec

Title: US-09-817-387-16

Perfect score: 23

Sequence: 1 gractgctcagguagguuag 23

Scoring table: IDENTITY NUC

Gapop 10.0, Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 2989766

Minimum DB seq length: 0

Maximum DB seq length: 200

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

N Geneseq 19Jun03:\*

- 1: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1980.DAT.\*
- 2: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1981.DAT.\*
- 3: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1982.DAT.\*
- 4: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1983.DAT.\*
- 5: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1984.DAT.\*
- 6: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1985.DAT.\*
- 7: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1986.DAT.\*
- 8: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1987.DAT.\*
- 9: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1988.DAT.\*
- 10: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1989.DAT.\*
- 11: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1990.DAT.\*
- 12: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1991.DAT.\*
- 13: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1992.DAT.\*
- 14: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1993.DAT.\*
- 15: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1994.DAT.\*
- 16: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1995.DAT.\*
- 17: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1996.DAT.\*
- 18: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1997.DAT.\*
- 19: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1998.DAT.\*
- 20: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA1999.DAT.\*
- 21: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA2000.DAT.\*
- 22: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA2001A.DAT.\*
- 23: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA2001B.DAT.\*
- 24: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA2002.DAT.\*
- 25: /SIDSI1/gcgdata/geneseq/geneseq-emb1/NA2003.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
C 1	16.6	72.2	65	ABN56789	Mouse spliced tran
C 2	16.6	72.2	163	AAQ06654	Feline T-cell lymph
C 3	16.2	70.4	134	ABV05840	Human prostate exp
C 4	15.8	68.7	179	AAZ42331	Human 5' EST isola
C 5	15.6	67.8	44	AAT69647	Telomerase amplifi
C 6	15.2	66.1	51	AAI30461	Human SNP oligonuc
C 7	15.2	66.1	145	AAI30461	Human secreted pro
C 8	15	65.2	18	AAT69649	Telomerase competi

C 9	15	65.2	21	18	AAT66719	Telomerase 3' end
C 10	15	65.2	24	19	AAV49634	Telomerase primer
C 11	15	65.2	29	19	AAV05785	Probe 1 for telome
C 12	15	65.2	29	19	AAV05786	Probe 2 for telome
C 13	15	65.2	29	19	AAV05787	Probe 3 for telome
C 14	15	65.2	29	19	AAV05788	Probe 4 for telome
C 15	15	65.2	29	22	AAH45829	Telomere size dete
C 16	15	65.2	34	19	AAV05774	TRAP assay primer.
C 17	15	65.2	39	21	AAZ96507	T cell antigen rec
C 18	15	65.2	48	19	AAV49636	Telomerase primer
C 19	15	65.2	51	22	AAH40136	Human SNP flanking
C 20	15	65.2	62	18	AAT66718	Telomerase activit
C 21	15	65.2	62	24	ABK10342	Zinc finger protei
C 22	15	65.2	68	24	ABK10341	Zinc finger protei
C 23	15	65.2	70	19	AAV49629	Synthetic telomera
C 24	14.8	64.3	172	25	ABX27421	Human GDP-mannose
C 25	14.6	63.5	95	20	AAV36847	Human XLIIS gene fr
C 26	14.6	63.5	132	22	ABA69705	Human foetal liver
C 27	14.4	62.6	139	24	ABV88601	Human colon cancer
C 28	14.4	62.6	181	25	ABX85127	Corn ear-derived p
C 29	14.4	62.6	192	25	ABX61117	Arabidopsis thalia
C 30	14.2	61.7	28	19	AAV40551	Homo sapiens secre
C 31	14.2	61.7	53	25	ABZ81709	Probe for DNase I
C 32	14.2	61.7	60	20	AAV63551	PCR standard prime
C 33	14.2	61.7	71	18	AAV76032	Staphylococcus aur
C 34	14.2	61.7	165	24	ABN23030	Human ORFX polynuc
C 35	14.2	61.7	167	20	AAV86237	EST clone AA35. H
C 36	14	60.9	25	22	AAH40135	SNP specific SNPE
C 37	14	60.9	32	19	AAV05777	Probe for T7 promo
C 38	14	60.9	35	22	AD06032	Yeast cyathionin
C 39	14	60.9	90	24	ABK36358	HIV DNA encoding T
C 40	14	60.9	100	24	ABK36958	Hiv subcasette PC
C 41	14	60.9	200	20	AAH86174	Human single nucle
C 42	13.8	60.0	36	10	AAH90556	Tissue plasminogen
C 43	13.8	60.0	53	25	ABZ81710	Probe for DNase I
C 44	13.8	60.0	60	24	ABN43817	Human spliced tran
C 45	13.8	60.0	98	25	ABX54057	Bovine EST associa

ALIGNMENTS

RESULT 1

ABN56789/c

ID ABN56789 standard; DNA; 65 BP.

XX AC ABN56789;

XX DT 15-JUL-2002 (first entry)

XX DE Mouse spliced transcript detection oligonucleotide SEQ ID NO:29537.

XX KW Human; mouse; rat; splice transcript; detection; RNA transcript;

XX KM splice variant; transcriptome; oligonucleotide library; ss.

XX OS Mus musculus.

XX PN WO200210449-A2.

XX PD 07-FEB-2002.

XX XX 20-JUL-2001; 2001WO-1B01903.

XX XX 28-JUL-2000; 2000US-221607P.

XX PR 02-MAY-2001; 2001US-287724P.

XX XX (COMP-) COMPUGEN INC.

XX XX Shoshan A, Wasserman A, Mintz E, Mintz L, Faigler S;

XX XX WPI; 2002-257383/30.

XX PT New oligonucleotide libraries comprising oligonucleotides which

PT selectively hybridize to mRNAs transcribed from a transcription unit of  
 PT a genome, useful for detecting tissue-, pathology-, and  
 PT developmental-specific genes -

XX Example 1; SEQ ID 29537; 47pp; English.

XX The present invention describes oligonucleotide libraries for detecting  
 CC messenger RNAs that populate a (sub-)transcriptome, where the  
 CC (sub-)transcriptome comprises messenger RNAs transcribed from multiple  
 CC transcription units that populate a genome. The library comprises  
 CC several oligonucleotides, each capable of hybridising selectively to a  
 CC set of messenger RNAs transcribed from a given transcription unit of  
 CC the genome, which encodes one or more messenger RNA splice variants.  
 CC The oligonucleotide libraries are useful for detecting mRNAs from a  
 CC biological sample, in expression profiling studies, in qualitatively or  
 CC quantitatively characterising the corresponding transcriptome, and in  
 CC detecting RNA transcripts and splice variants of human or animal  
 CC transcriptomes. The libraries may also be used as specialised mini  
 CC libraries to detect transcripts of a sub-transcriptome under a  
 CC particular biological or pathological state, and so allowing the  
 CC detection of tissue- and pathology-specific genes such as those genes  
 CC only expressed in specific tissue under a specific pathological  
 CC condition; to detect developmental specific genes; and to detect RNA  
 CC transcripts and splice variants of a transcriptome of a patient suffering  
 CC from a particular disorder. ABN7253 to ABN59589 represent  
 CC oligonucleotide sequences from rats, humans and mice, which are used in  
 CC the exemplification of the present invention.  
 CC N.B. The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from WIPO  
 CC at ftp.wipo.int/pub/published\_pct\_sequences.

SQ Sequence 65 BP; 17 A; 18 C; 16 G; 14 T; 0 other;

Query Match 72.2%; Score 16.6; DB 24; Length 65;  
 Best Local Similarity 69.6%; Pred. No. 1.6e+02;  
 Matches 16; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY 1 GTACTGCTCAGAGUAGGGUAG 23  
 ||| |||||:|:|:|:|:  
 DB 47 GTAGTCTCAGAGTTTGGGTAG 25

RESULT 2  
 AAQ06654/C  
 ID AAQ06654 standard; DNA; 163 BP.  
 XX  
 XX AAQ06654;  
 AC  
 XX  
 DT 26-FEB-1991 (first entry)  
 XX  
 DE Feline T-cell lymphotropic lentivirus of clone 2BYCXL2.  
 XX  
 XX Feline T-cell lymphotropic lentivirus; FIV; 2BYCXL2; antibodies;  
 KW vaccines; ds.  
 XX  
 XX Feline T-cell lymphotropic lentivirus 2428 (Pentaluma).  
 OS

XX Key Location/Qualifiers  
 FH 2..163  
 FT CDS /\*tag= a  
 FT /label=FIV

XX WO9013573-A.  
 XX  
 XX 15-NOV-1990.  
 XX  
 XX 30-APR-1990; 90WO-US02338.  
 XX  
 XX 08-DEC-1989; 89US-0447810.  
 PR 08-MAY-1989; 89US-0348784.  
 XX  
 XX (IDEX-) IDEXX CORP.

XX

PI Anderson PR, Oconnor TP, Tonelli QJ;  
 XX WPI; 1990-361429/48.  
 DR P-PSDB; AAR08085.  
 XX

PT Feline T-cell lympho-tropic lentivirus poly-peptide(s) - used for  
 PT specific detection of FIV antibodies, prodn. of antibodies and in  
 PT vaccines

XX Disclosure; Fig 5(b); 37pp; English.

XX FIV nucleic acid is useful for prodn. of large amts. of FIV  
 CC polypeptides, or fragments, and also for the detection of homologous  
 CC nucleic acids in vivo. The amino acid sequence derived from this  
 CC sequence shows homology with the envelope gene of equine infectious  
 CC anemia virus, a lentivirus, immunologically closely related to FIV.  
 CC Nucleic acid probes derived from the 2BY DNA hybridises to DNA  
 CC isolated from FIV infected but not uninfected cells.  
 CC Strain 2BY has been deposited ATCC 67938.  
 CC See also AAQ06653-55 and AAR08094-96.

XX Sequence 163 BP; 28 A; 66 C; 37 G; 30 T; 2 other;

Query Match 72.2%; Score 16.6; DB 11; Length 163;  
 Best Local Similarity 65.2%; Pred. No. 1.8e+02;  
 Matches 15; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 1 GTACTGCTCAGAGUAGGGUAG 23  
 ||| |||||:|:|:|:|:  
 DB 118 GTAGGGCTTAGGGTTAGGGTTAG 96

RESULT 3  
 ABV05840/C  
 ID ABV05840 standard; cDNA; 134 BP.  
 XX

AC ABV05840;

XX 13-SEP-2002 (first entry)

XX Human prostate expression marker cDNA 5831.

XX Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;  
 KW pharmacogenomic marker; gene; ss.

XX Homo sapiens.

XX WO200160860-A2.

XX 23-AUG-2001.

XX 20-FEB-2001; 2001WO-US05171.

XX 17-FEB-2000; 2000US-183319P.

XX 16-MAR-2000; 2000US-189862P.

XX 25-MAY-2000; 2000US-207454P.

XX 09-JUN-2000; 2000US-211314P.

XX 18-JUL-2000; 2000US-219007P.

XX 13-DEC-2000; 2000US-255281P.

XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

XX Schlegel R, Endege WO, Monahan JE;

XX WPI; 2001-662795/76.

XX Novel isolated nucleic acid molecule associated with cancerous state of  
 PT prostate cells and correlating with presence of prostate cancer, useful  
 PT for detecting presence of prostate cancer, stage of prostate cancer -

XX Claim 1; Page 972; 11750pp; English.

XX The invention relates to an isolated nucleic acid molecule (I) comprising

CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the  
 CC specification or its complement. (1) is useful for:  
 CC (a) assessing whether a patient is afflicted with prostate cancer;  
 CC (b) monitoring the progression of prostate cancer in a patient;  
 CC (c) assessing the efficacy of a test compound to inhibit prostate  
 CC cancer in a patient;  
 CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer  
 CC in a patient;  
 CC (e) selecting a composition for inhibiting prostate cancer in a patient;  
 CC (f) assessing the prostate cell carcinogenic potential of a compound;  
 CC (g) determining whether prostate cancer has metastasized in a patient;  
 CC (h) assessing the aggressiveness or indolence of prostate cancer in a  
 CC patient;  
 CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.  
 XX  
 SQ Sequence 134 BP; 27 A; 34 C; 25 G; 43 T; 5 other;  
 Query Match 70.4%; Score 16.2; DB 23; Length 134;  
 Best Local Similarity 71.4%; Pred. No. 2.8e+02;  
 Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;  
 QY 1 GTACTGCTCAGAGUAGGGU 21  
 ||||| :||| :||| :  
 Db 96 GTACTGCTCGAGGTGGTT 76  
 RESULT 4  
 ID AA242331/c  
 ID AA242331 standard; cDNA; 179 BP.  
 XX  
 AC AA242331;  
 XX  
 DT 01-FEB-2000 (first entry)  
 XX  
 DE Human 5' EST isolated from a cDNA library SEQ ID NO:90.  
 XX  
 KW Human; 5' EST; expressed sequence tag; secreted protein; diagnosis;  
 KW gene therapy; chromosome mapping; upstream regulatory sequence;  
 KW forensic; location; development; protein synthesis; stability;  
 KW regulation; identification; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN W09953051-A2.  
 XX  
 PD 21-OCT-1999.  
 XX  
 PF 09-APR-1999; 99WO-IB00712.  
 XX  
 PR 09-APR-1998; 98US-0057719.  
 PR 28-APR-1998; 98US-0069047.  
 XX  
 PA (GSEST ) GENSET.  
 XX  
 PI Dumas Milne Edwards J, Duclert A, Giordano J;  
 XX  
 DR WPI; 2000-038446/03.  
 DR P-PSDB; AAY64717.  
 XX  
 PT Novel secreted protein 5' expressed sequence tag sequences used in  
 PT diagnostic, forensic, gene therapy, and chromosome mapping procedures  
 XX  
 PS Claim 1; Page 223; 837pp; English.  
 XX  
 CC AA242265 to AA243075 represent novel 5' expressed sequence tag (EST)  
 CC sequences, corresponding to human secreted proteins. AAY64651 to  
 CC AAY65438 correspond the EST-related proteins corresponding to AA242265 to  
 CC AA243052. The 5' ESTs can be used for producing secreted human gene  
 CC products. They can be used to identify and isolate 5' untranslated  
 CC regions (UTRs) and upstream regulatory regions which control the  
 CC location, development stage, rate, and quantity of protein synthesis, as  
 CC well as stability of mRNA. The ESTs are also useful as probes for  
 CC chromosome mapping, and to obtain full length cDNA clones. The ESTs can

CC also be used in forensic procedures to identify individuals, or in  
 CC diagnostic procedures to identify individuals having genetic diseases  
 CC resulting from abnormal gene expression. The products may also be used in  
 CC gene therapy protocols. The nucleic acids encoding signal peptides can be  
 CC used for directing extracellular secretion of a polypeptide or the  
 CC insertion of a polypeptide into a membrane, or importing a polypeptide  
 CC into a cell. The proteins encoded by the EST sequences may be useful in  
 CC treating a variety of human conditions. Secreted proteins have  
 CC therapeutic value, and the identification of new secreted proteins is  
 CC valuable. AA242249 to AA242264 and AAY64644 to AAY64650 represent  
 CC sequences used in the exemplification of the present invention.  
 XX  
 SQ Sequence 179 BP; 26 A; 67 C; 34 G; 39 T; 13 other;  
 Query Match 68.7%; Score 15.8; DB 21; Length 179;  
 Best Local Similarity 71.4%; Pred. No. 4.4e+02;  
 Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;  
 QY 3 ACTGCTCAGAGUAGGGUAG 23  
 ||||| :||| :||| :  
 Db 165 ACTGCTCAGATKCGAGTGAG 145  
 RESULT 5  
 ID AAT69647/c  
 ID AAT69647 standard; DNA; 44 BP.  
 XX  
 AC AAT69647;  
 XX  
 DT 20-FEB-1998 (first entry)  
 XX  
 DE Telomerase amplification primer TE-ACT-ST.  
 XX  
 KW Telomerase; substrate; primer; detection; 5'-region; retrovirus;  
 KW long terminal repeat 2; LTR-2; diagnosis; tumour; screening;  
 KW effector compound; PCR; amplification; ss.  
 XX  
 OS Synthetic.  
 XX  
 PN DE19644302-A1.  
 XX  
 PD 05-JUN-1997.  
 XX  
 PF 24-OCT-1996; 96DE-1044302.  
 XX  
 PR 28-NOV-1995; 95DE-1044317.  
 XX  
 PA (BOEF ) BOEHRINGER MANNHEIM GMBH.  
 XX  
 PI Erich T, Hinzpeter M, Karl G, Leying H;  
 XX  
 DR WPI; 1997-299542/28.  
 XX  
 PT Measuring telomerase activity, useful for tumour diagnosis and  
 PT compound screening - by extending substrate primer, followed by  
 PT amplification and immobilising product for detection  
 XX  
 PS Example; Page 13; 21pp; German.  
 XX  
 CC The present sequence is a telomerase amplification primer, which  
 CC can be used in a novel method for detecting telomerase activity.  
 CC The method comprises adding to a test sample a 1st primer, that  
 CC serves as telomerase substrate, and nucleoside triphosphate (dNTP)  
 CC and incubating to allow primer extension by the telomerase,  
 CC amplifying the extension product, immobilising the amplification  
 CC product (AP) on a solid phase and qualitative and/or quantitative  
 CC detection of AP, where the substrate primer is preferably from the  
 CC 5'-region of the long terminal repeat 2 (LTR-2) sequence of a  
 CC retrovirus. The method can be used to diagnose tumours and screen  
 CC compounds for effector activity. Immobilisation of AP provides a  
 CC signal that is reproducibly representative of telomerase activity,  
 CC eliminates the need for gel electrophoretic separation and  
 CC provides high sensitivity. Radioactive labels are not required and

CC the method can be automated for routine use. Specific detection is  
 CC achieved by proper choice of hybridisation conditions, without  
 CC separation of the telomerase extension product. A specific signal  
 CC is generated by 1-10 cell equivalents, but for tumour analysis  
 CC 10-1000 ng of tissue is usually used.

XX Sequence 44 BP; 13 A; 16 C; 9 G; 6 T; 0 other;  
 SQ Query Match 67.8%; Score 15.6; DB 18; Length 44;  
 Best Local Similarity 63.6%; Pred. No. 4.8e+02;  
 Matches 14; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 2 TACTGCTCAGAGUAGGGUAG 23  
 ||||| :|||:|||||  
 DB 28 TTCTGGTTAGGTTAGGTTAG 7

RESULT 6  
 AAL30461  
 ID AAL30461 standard; DNA; 51 BP.  
 XX AC AAL30461;  
 XX AC AAL30461;  
 DT 24-JAN-2002 (first entry)  
 XX DE Human SNP oligonucleotide #3669.

XX KW Immunosuppressive; immunostimulatory; antiinflammatory; cytostatic;  
 KW neuroprotective; antimicrobial; gene therapy; vaccine; amylase; cancer;  
 KW amyloid protein; angiotensin; apoptosis related protein; cadherin;  
 KW cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;  
 KW complement related protein; cytochrome; kinesin; cytokine; interferon;  
 KW interleukin; G-protein coupled receptor; thioesterase; inflammation;  
 KW multifactorial disease; autoimmune disease; infection;  
 KW nervous system disease; ss.

XX OS Homo sapiens.  
 XX WO200147944-A2.  
 XX 05-JUL-2001.  
 XX 28-DEC-2000; 2000WO-US35498.  
 XX 28-DEC-1999; 99US-0173419.  
 XX 27-DEC-2000; 2000US-0173419.  
 XX (CURA-) CURAGEN CORP.  
 XX PI Shinkets RA, Leach M;  
 XX WPI; 2001-465210/50.  
 XX Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases,  
 PT oncogenes and histones, useful for diagnosing and treating, e.g.  
 PT cancer, autoimmune diseases and infections -  
 PS Claim 1; Page 2440; 4143pp; English.

XX The present invention relates to oligonucleotides encoding polymorphic  
 CC variants of proteins related to amylases, amyloid protein, angiotensin,  
 CC apoptosis related proteins, cadherin, cyclin, polymerase, oncogenes,  
 CC histones, kinases, colony stimulating factors, complement related  
 CC proteins, cytochromes, kinesins, cytokines, interferons, interleukins,  
 CC G-protein coupled receptors and thioesterases. The present sequence is  
 CC one such oligonucleotide. The oligonucleotides and the peptides encoded  
 CC by them may be used in the prevention, diagnosis and treatment of  
 CC diseases associated with inappropriate expression of the proteins listed  
 CC above. Disorders that may be prevented, diagnosed and/or treated include  
 CC multifactorial diseases with a genetic component, such as autoimmune  
 CC diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes, cancer  
 CC systemic lupus erythematosus and Grave's disease), inflammation, cancer  
 CC (e.g. cancers of the bladder, brain, breast, colon and kidney.

CC leukaemia), diseases of the nervous system and an infection of pathogenic  
 CC organisms.  
 XX Sequence 51 BP; 14 A; 8 C; 13 G; 16 T; 0 other;  
 SQ Query Match 66.1%; Score 15.2; DB 22; Length 51;  
 Best Local Similarity 70.0%; Pred. No. 7.6e+02;  
 Matches 14; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 4 CTGCTCAGAGUAGGGUAG 23  
 ||||| :|||:|||||  
 DB 25 CTGCTCAGATTAGGGTGAG 44

RESULT 7  
 AAC26003/c  
 ID AAC26003 standard; cDNA; 145 BP.  
 XX AC AAC26003;  
 XX AC AAC26003;  
 DT 06-OCT-2000 (first entry)  
 XX DE Human secreted protein 5' EST, SEQ ID NO: 30078.  
 XX KW Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;  
 KW gene therapy; chromosome mapping; ss.

XX OS Homo sapiens.  
 XX EP1033401-A2.  
 XX 06-SEP-2000.  
 XX 21-FEB-2000; 2000EP-0200610.  
 XX 26-FEB-1999; 99US-0122487.  
 XX (GEST.) GENSET.  
 XX Dumas Milne Edwards J, Duclert A, Giordano J;  
 XX WPI; 2000-500381/45.  
 XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for  
 PT obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for  
 PT diagnostic, forensic, gene therapy and chromosome mapping procedures -  
 XX Claim 1; SEQ ID 30078; 71pp + CD-ROM; English.

XX The present sequence is one of a large number of 5' ESTs derived from  
 CC mRNAs encoding secreted proteins. No ORF has yet been conclusively  
 CC identified within the present sequence. The 5' ESTs were prepared from  
 CC total human RNAs or polyA+ RNAs derived from 30 different tissues. EST  
 CC sequences usually correspond mainly to the 3' untranslated region (UTR)  
 CC of the mRNA because they are often obtained from oligo-dT primed cDNA  
 CC libraries. Such ESTs are not well suited for isolating cDNA sequences  
 CC derived from the 5' ends of mRNAs and even in those cases where longer  
 CC cDNA sequences have been obtained, the full 5' UTR is rarely included.  
 CC 5' ESTs are derived from mRNAs with intact 5' ends and can therefore be  
 CC used to obtain full length cDNAs and genomic DNAs. 5' ESTs are also used  
 CC in diagnostic, forensic, gene therapy and chromosome mapping procedures.  
 CC They are used to obtain upstream regulatory sequences and to design  
 CC expression and secretion vectors.

XX Sequence 145 BP; 39 A; 33 C; 19 G; 54 T; 0 other;  
 SQ Query Match 66.1%; Score 15.2; DB 21; Length 145;  
 Best Local Similarity 75.0%; Pred. No. 8.5e+02;  
 Matches 15; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 3 ACTGCTCAGAGUAGGGUUA 22  
 ||||| :|||:|||||  
 DB 124 ACTGCTCAGAGTCAGGGTGA 105

```

RESULT 8
AAT69649/c
ID AAT69649 standard; DNA; 18 BP.
XX
AC AAT69649;
XX
XX 20-FEB-1998 (first entry)
XX
XX Telomerase competitor oligonucleotide.
XX
XX Telomerase; substrate; primer; detection; 5'-region; retrovirus;
KW long terminal repeat 2; LTR-2; diagnosis; tumour; screening;
KW effector compound; PCR; competitor oligonucleotide; ss.
XX
XX Synthetic.
XX
XX DE19644302-A1.
XX
XX 05-JUN-1997.
XX
XX 24-OCT-1996; 96DE-1044302.
XX
XX 28-NOV-1995; 95DE-1044317.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Emrich T, Hinzper M, Karl G, Leying H;
XX
XX WPI; 1997-299542/28.
XX
XX Measuring telomerase activity, useful for tumour diagnosis and
PT compound screening - by extending substrate primer, followed by
PT amplification and immobilising product for detection
XX
XX Example; Page 13; 21pp; German.
XX
XX The present sequence is a telomerase competitor oligonucleotide,
CC which can be used in a novel method for detecting telomerase
CC activity. The method comprises adding to a test sample a 1st
CC primer, that serves as telomerase substrate, and nucleoside
CC triphosphate (dNTP) and incubating to allow primer extension by the
CC telomerase, amplifying the extension product, immobilising the
CC amplification product (AP) on a solid phase and qualitative and/or
CC quantitative detection of AP, where the substrate primer is
CC preferably from the 5'-region of the long terminal repeat 2 (LTR-2)
CC sequence of a retrovirus. The method can be used to diagnose
CC tumours and screen compounds for effector activity. Immobilisation
CC of AP provides a signal that is reproducibly representative of
CC telomerase activity, eliminates the need for gel electrophoretic
CC separation and provides high sensitivity. Radioactive labels are
CC not required and the method can be automated for routine use.
CC Specific detection is achieved by proper choice of hybridisation
CC conditions, without separation of the telomerase extension product.
CC A specific signal is generated by 1-10 cell equivalents, but for
XX tumour analysis 10-1000 ng of tissue is usually used.
XX
SQ Sequence 18 BP; 4 A; 8 C; 1 G; 5 T; 0 other;
Query Match 65.2%; Score 15; DB 18; Length 18;
Best Local Similarity 73.3%; Pred. No. 8.4e+02;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 9 CAGAGUAGGGGUAG 23
|||||:|||||:|
DB 16 CAGAGTTAGGTTAG 2

RESULT 9
AAT66719/c
ID AAT66719 standard; DNA; 21 BP.
XX

```

```

AC AAT66719;
XX
XX 17-DEC-1997 (first entry)
XX
XX Telomerase 3' end and telomeric repeat junction probe.
XX
XX Telomerase activity; cancer; human; somatic cell; infertility;
KW foetal cell; maternal blood; bone marrow; proliferation; protozoa;
KW fungal infection; ss.
XX
XX Synthetic.
XX
XX WO9715687-A1.
XX
XX 01-MAY-1997.
XX
XX 07-JUN-1996; 96WO-US09669.
XX
XX 15-APR-1996; 96US-0632662.
XX
XX 07-JUN-1995; 95US-0482132.
XX
XX 12-APR-1996; 96US-0631554.
XX
XX (GERO-) GERON CORP.
XX
XX Harley CB, Kim NW, Weinrich SL;
XX
XX WPI; 1997-259038/23.
XX
XX Testing cell sample for telomerase activity - by incubating with
PT substrate to form extended product which is replicated and detected,
PT useful for cancer prognosis, diagnosis and monitoring
XX
XX Disclosure; Page 25; 96pp; English.
XX
XX A method has been developed for testing a cell sample for telomerase
CC (TM) activity. The method involves: (a) incubating the cell, or its
CC extract, with a TM substrate so that it is extended by addition of
CC telomeric repeats; (b) replicating the extended substrate; and (c)
CC correlating the presence or absence of TM activity with presence or
CC absence of the extended substrate. The present sequence represents a
CC probe corresponding to the junction between the 3' end of telomerase
CC and the telomeric repeats of the telomerase product. The method can be
CC used to test for elevated levels of TM in human somatic cells, i.e. in
CC the diagnosis, prognosis and monitoring of cancer. Also low levels of TM
CC are associated with infertility, TM may indicate foetal cells in
CC maternal blood and TM can be a marker for bone marrow proliferation and
CC infection by protozoa or fungi. The method can also be used to identify,
CC screen and design telomerase inhibitors. The method is simple,
CC inexpensive, suitable for automation to provide a high throughput system
XX and all the steps can be carried out in a single reaction vessel.
XX
SQ Sequence 21 BP; 6 A; 9 C; 1 G; 5 T; 0 other;
Query Match 65.2%; Score 15; DB 18; Length 21;
Best Local Similarity 73.3%; Pred. No. 8.6e+02;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 9 CAGAGUAGGGGUAG 23
|||||:|||||:|
DB 19 CAGAGTTAGGTTAG 5

RESULT 10
AAV49634/c
ID AAV49634 standard; DNA; 24 BP.
XX
XX AAV49634;
XX
XX 21-OCT-1998 (first entry)
XX
XX Telomerase primer OLS.
XX
XX Telomerase; detection; hybridisation; sensitivity; primer; ss.

```



```

XX OS Synthetic.
XX PN DE19705071-A1.
XX PD 13-AUG-1998.
XX PF 11-FEB-1997; 97DE-1005071.
XX PR 11-FEB-1997; 97DE-1005071.
XX PA (HEID/) HEIDORN K.
XX PA (KRUP/) KRUPP G.
XX PA (PARW/) PARWARESCH R.
XX PI Heidorn K, Krupp G, Parwaresch R;
XX WI; 1998-438335/38.
XX PT Determination of telomerase by primer extension and amplification -
PT using reverse primer unable to generate long products following
PT artificial dimer formation, increases sensitivity and eliminates
PT false positives
XX PS Example; Fig 4; 10pp; German.
XX CC AAV49627-V49636 are primers used in a method for detecting telomerase
CC with high reliability and very low detection limit. The method involves
CC a reverse primer that has an internal sequence designed so that long
CC products can not be formed by misplaced hybridisation from the
CC artificially formed primer dimer. Use of the specified reverse primer
CC avoids false positives and increases sensitivity, particularly allowing
CC detection of telomerase in single cells and reliable differentiation
CC between negative controls and weakly positive samples. The method can be
CC analysed in real time, i.e. detection is made during the polymerase
CC chain reaction (PCR), eliminating the need for a separation step by gel
CC electrophoresis. This results in a very rapid, easily automated and
CC quantifiable process, and in some embodiments detection can be with a
CC simple fluorescent photometer.
XX SQ Sequence 24 BP; 6 A; 12 C; 1 G; 5 T; 0 other;

Query Match 65.2%; Score 15; DB 19; Length 24;
Best Local Similarity 73.3%; Pred. No. 8.7e+02;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 9 CAGAGUAGGGUAG 23
DB 23 CAGAGTTAGGGTTAG 9

RESULT 11
AAV05785/c
ID AAV05785 standard; DNA; 29 BP.
XX AC AAV05785;
XX DT 19-JUN-1998 (first entry);
XX DE Probe 1 for telomerase.
XX KW PCR primer; telomerase; telomerase activity detection; cancer cell;
XX KW diagnosis; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX modified_base 14..15
XX /*tag= a
XX /*note= "backbone modified with acridinium ester"
XX PN W09800563-A1.
XX PD 08-JAN-1998.

```

```

PD 08-JAN-1998.
XX PF 27-JUN-1997; 97WO-JP02251.
XX PR 28-JUN-1996; 96JP-0169920.
XX PA (CHUS ) CHUGAI SEIYAKU KK.
XX PI Hashimoto J, Hirose M, Yoshimura T;
XX WI; 1998-086987/08.
XX PT Detection of telomerase activity in cells for cancer diagnosis - by
PT telomeric repeat amplification protocol followed by hybridisation
PT protection assay using a non-radioactive (chemoluminescent) label
XX PS Disclosure; Page 26; 58pp; Japanese.
XX CC This sequence represents a probe used in the method
CC of the invention. The method is for the detection of telomerase activity
CC in cells, by: (1) elongating a telomerase substrate (TS primer) using the
CC cell telomerase; amplifying the elongated substrate by polymerase chain
CC reaction (PCR) using a second primer (CX primer); (2) hybridising the
CC amplification product with a probe labelled with a non-radioactive
CC (preferably chemoluminescent) label; and (3) assaying the label.
CC Alternatively the TS primer is attached to a promoter sequence (e.g. T7
CC RNA polymerase, T3 RNA polymerase or SP6 RNA polymerase promoter) and the
CC elongated substrate is amplified using an RNA polymerase to synthesise
CC multiple RNA copies of the sequence and a reverse transcriptase to form
CC DNA copies. Detection of cancer cells and diagnosis of cancer by
CC detection of telomerase activity in the cells. This may be by invasive
CC methods (e.g. biopsy of tissue from bladder, uterus, cervix, spleen,
CC liver, mammary, colon, stomach, lung, kidney, skin, oesophagus, brain,
CC mouth etc) or non-invasive methods (e.g. examination of biological
CC samples such as urine, uterine smear, bladder washings, mouth washings,
CC colonic washings, duodenal secretion, saliva, sputum, etc). The method is
CC rapid and of high sensitivity, and does not require the use of a
CC radioactive label.
XX SQ Sequence 29 BP; 6 A; 14 C; 2 G; 7 T; 0 other;

Query Match 65.2%; Score 15; DB 19; Length 29;
Best Local Similarity 73.3%; Pred. No. 8.9e+02;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 9 CAGAGUAGGGUAG 23
DB 23 CAGAGTTAGGGTTAG 9

RESULT 12
AAV05786/c
ID AAV05786 standard; DNA; 29 BP.
XX AC AAV05786;
XX DT 19-JUN-1998 (first entry)
XX DE Probe 2 for telomerase.
XX KW PCR primer; telomerase; telomerase activity detection; cancer cell;
XX KW diagnosis; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX modified_base 15..16
XX /*tag= a
XX /*note= "backbone modified with acridinium ester"
XX PN W09800563-A1.
XX PD 08-JAN-1998.

```

```

XX PF 27-JUN-1997; 97WO-JP02251.
XX PR 28-JUN-1996; 96JP-0169920.
XX PA (CHUS ) CHUGAI SEIYAKU KK.
XX PI Hashimoto J, Hirose M, Yoshimura T;
XX DR WPI; 1998-086987/08.
XX XX
XX PT Detection of telomerase activity in cells for cancer diagnosis - by
XX PT telomeric repeat amplification protocol followed by hybridisation
XX PT protection assay using a non-radioactive (chemoluminescent) label
XX PS Disclosure; Page 26; 58pp; Japanese.
XX CC This sequence represents a probe used in the method
XX CC of the invention. The method is for the detection of telomerase activity
XX CC in cells, by: (1) elongating a telomerase substrate (TS primer) using the
XX CC cell telomerase; amplifying the elongated substrate by polymerase chain
XX CC reaction (PCR) using a second primer (CX primer); (2) hybridising the
XX CC amplification product with a probe labelled with a non-radioactive
XX CC (preferably chemoluminescent) label; and (3) assaying the label.
XX CC Alternatively the TS primer is attached to a promoter sequence (e.g. T7
XX CC RNA polymerase, T3 RNA polymerase or SP6 RNA polymerase promoter) and the
XX CC elongated substrate is amplified using an RNA polymerase to synthesise
XX CC multiple RNA copies of the sequence and a reverse transcriptase to form
XX CC DNA copies. Detection of cancer cells and diagnosis of cancer by
XX CC detection of telomerase activity in the cells. This may be by invasive
XX CC methods (e.g. biopsy of tissue from bladder, uterus, cervix, spleen,
XX CC liver, mammary, colon, stomach, lung, kidney, skin, oesophagus, brain,
XX CC mouth etc) or non-invasive methods (e.g. examination of biological
XX CC samples such as urine, uterine smear, bladder washings, mouth washings,
XX CC colonic washings, duodenal secretion, saliva, sputum, etc). The method is
XX CC rapid and of high sensitivity, and does not require the use of a
XX CC radioactive label.
XX SQ Sequence 29 BP; 6 A; 14 C; 2 G; 7 T; 0 other;
      Query Match 65.2%; Score 15; DB 19; Length 29;
      Best Local Similarity 73.3%; Pred. No. 8.9e+02;
      Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 9 CAGAGUUAGGGUUAG 23
Db 23 CACAGTTAGGTTAG 9
      |||||:||||:|
      |||||:||||:|

RESULT 13
AAV05787/c
ID AAV05787 standard; DNA; 29 BP.
XX AC AAV05787;
XX DT 19-JUN-1998 (first entry)
XX DE Probe 3 for telomerase.
XX KW PCR primer; telomerase; telomerase activity detection; cancer cell;
XX KW diagnosis; ss.
XX OS Synthetic.
XX PH Key Location/Qualifiers
XX FT modified_base 9..10
XX FT /*tag= a
XX FT /note= "backbone modified with acridinium ester"
XX PN WO9800563-A1.
XX PD 08-JAN-1998.
XX PF 27-JUN-1997; 97WO-JP02251.

XX PF 27-JUN-1997; 97WO-JP02251.
XX PR 28-JUN-1996; 96JP-0169920.
XX PA (CHUS ) CHUGAI SEIYAKU KK.
XX PI Hashimoto J, Hirose M, Yoshimura T;
XX DR WPI; 1998-086987/08.
XX XX
XX PT Detection of telomerase activity in cells for cancer diagnosis - by
XX PT telomeric repeat amplification protocol followed by hybridisation
XX PT protection assay using a non-radioactive (chemoluminescent) label
XX PS Disclosure; Page 27; 58pp; Japanese.
XX CC This sequence represents a probe used in the method
XX CC of the invention. The method is for the detection of telomerase activity
XX CC in cells, by: (1) elongating a telomerase substrate (TS primer) using the
XX CC cell telomerase; amplifying the elongated substrate by polymerase chain
XX CC reaction (PCR) using a second primer (CX primer); (2) hybridising the
XX CC amplification product with a probe labelled with a non-radioactive
XX CC (preferably chemoluminescent) label; and (3) assaying the label.
XX CC Alternatively the TS primer is attached to a promoter sequence (e.g. T7
XX CC RNA polymerase, T3 RNA polymerase or SP6 RNA polymerase promoter) and the
XX CC elongated substrate is amplified using an RNA polymerase to synthesise
XX CC multiple RNA copies of the sequence and a reverse transcriptase to form
XX CC DNA copies. Detection of cancer cells and diagnosis of cancer by
XX CC detection of telomerase activity in the cells. This may be by invasive
XX CC methods (e.g. biopsy of tissue from bladder, uterus, cervix, spleen,
XX CC liver, mammary, colon, stomach, lung, kidney, skin, oesophagus, brain,
XX CC mouth etc) or non-invasive methods (e.g. examination of biological
XX CC samples such as urine, uterine smear, bladder washings, mouth washings,
XX CC colonic washings, duodenal secretion, saliva, sputum, etc). The method is
XX CC rapid and of high sensitivity, and does not require the use of a
XX CC radioactive label.
XX SQ Sequence 29 BP; 7 A; 11 C; 4 G; 7 T; 0 other;
      Query Match 65.2%; Score 15; DB 19; Length 29;
      Best Local Similarity 73.3%; Pred. No. 8.9e+02;
      Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

OY 9 CAGAGUUAGGGUUAG 23
Db 18 CAGAGTTAGGTTAG 4
      |||||:||||:|
      |||||:||||:|

RESULT 14
AAV05788/c
ID AAV05788 standard; DNA; 29 BP.
XX AC AAV05788;
XX DT 19-JUN-1998 (first entry)
XX DE Probe 4 for telomerase.
XX KW PCR primer; telomerase; telomerase activity detection; cancer cell;
XX KW diagnosis; ss.
XX OS Synthetic.
XX PH Key Location/Qualifiers
XX FT modified_base 10..11
XX FT /*tag= a
XX FT /note= "backbone modified with acridinium ester"
XX PN WO9800563-A1.
XX PD 08-JAN-1998.
XX PF 27-JUN-1997; 97WO-JP02251.

```

XX 28-JUN-1996; 96JP-0169920.  
XX (CHUS ) CHUGAI SEIYAKU KK.  
XX Hashimoto J, Hirose M, Yoshimura T;  
XX WPI; 1998-086987/08.  
XX  
XX Detection of telomerase activity in cells for cancer diagnosis - by  
XX telomeric repeat amplification protocol followed by hybridisation  
XX protection assay using a non-radioactive (chemoluminescent) label  
XX  
XX Disclosure; Page 27; 58pp; Japanese.  
XX  
XX This sequence represents a probe used in the method  
XX of the invention. The method is for the detection of telomerase activity  
XX in cells, by: (1) elongating a telomerase substrate (TS primer) using the  
XX cell telomerase; amplifying the elongated substrate by polymerase chain  
XX reaction (PCR) using a second primer (CX primer); (2) hybridising the  
XX amplification product with a probe labelled with a non-radioactive  
XX (preferably chemoluminescent) label; and (3) assaying the label.  
XX Alternatively the TS primer is attached to a promoter sequence (e.g. T7  
XX RNA polymerase, T3 RNA polymerase or SP6 RNA polymerase promoter) and the  
XX elongated substrate is amplified using an RNA polymerase to synthesise  
XX multiple RNA copies of the sequence and a reverse transcriptase to form  
XX DNA copies. Detection of cancer cells and diagnosis of cancer by  
XX detection of telomerase activity in the cells. This may be by invasive  
XX methods (e.g. biopsy of tissue from bladder, uterus, cervix, spleen,  
XX liver, mammary, colon, stomach, lung, kidney, skin, oesophagus, brain,  
XX mouth etc) or non-invasive methods (e.g. examination of biological  
XX samples such as urine, uterine smear, bladder washings, mouth washings,  
XX colonic washings, duodenal secretion, saliva, sputum, etc). The method is  
XX rapid and of high sensitivity, and does not require the use of a  
XX radioactive label.  
XX  
XX Sequence 29 BP; 7 A; 11 C; 4 G; 7 T; 0 other;  
XX  
XX Query Match 65.2%; Score 15; DB 19; Length 29;  
XX Best Local Similarity 73.3%; Pred. No. 8.9e+02;  
XX Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX QY 9 CAGAGUAGGGUAG 23  
XX |||||:||||:||||  
XX Db 18 CAGAGTTAGGGTTAG 4  
XX  
XX RESULT 15  
XX AAH45829/c  
XX ID AAH45829 standard; DNA; 29 BP.  
XX  
XX AC AAH45829;  
XX  
XX DT 11-SEP-2001 (first entry)  
XX  
XX DE Telomere size determination method related oligonucleotide #2.  
XX  
XX KW Telomere size determination; chromosomal DNA; probe; primer;  
XX KW repetitive sequence; tissue aging; cancer progression; ss.  
XX  
XX OS Synthetic.  
XX  
XX FN JP2001095586-A.  
XX  
XX PD 10-APR-2001.  
XX  
XX PF 30-SEP-1999; 99JP-0279948.  
XX  
XX PR 30-SEP-1999; 99JP-0279948.  
XX  
XX PA (IDET/) IDE T.  
XX  
XX WPI; 2001-360495/38.

XX  
XX PT Determining telomere size useful for investigating aging in tissue and  
XX progression of cancer -  
XX  
XX PS Example 1; Page 5; 8pp; Japanese.  
XX  
XX CC The present invention describes a method for determining the length of  
XX telomeres, involving hybridising a chromosomal DNA extracted from a  
XX sample and a labeled DNA probe with a sequence complementary to a  
XX repetitive telomeric sequence, and measuring the labeled signal of the  
XX hybridised probe to give the size of telomere. This can be used to  
XX investigate tissue aging and the progression of cancer and in monitoring  
XX the prognosis of patients. The present sequence is an oligonucleotide  
XX probe described in the exemplification of the invention.  
XX  
XX SQ Sequence 29 BP; 7 A; 14 C; 2 G; 6 T; 0 other;  
XX  
XX Query Match 65.2%; Score 15; DB 22; Length 29;  
XX Best Local Similarity 73.3%; Pred. No. 8.9e+02;  
XX Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX QY 9 CAGAGUAGGGUAG 23  
XX |||||:||||:||||  
XX Db 23 CAGAGTTAGGGTTAG 9  
XX  
XX Search completed: November 8, 2003, 04:53:12  
XX Job time : 172 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2003, 04:47:47 ; Search time 1609 Seconds  
(without alignments)  
347.423 Million cell updates/sec

Title: US-09-817-387-16

Perfect score: 23

Sequence: 1 gractgctcagagguagguag 23

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 22781392 seqs, 12152238056 residues

Total number of hits satisfying chosen parameters: 2751168

Minimum DB seq length: 0

Maximum DB seq length: 200

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

```
EST:*
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_htc:*
9: gb_est1:*
10: gb_est2:*
11: gb_htc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rod:*
26: em_gss_phg:*
27: em_gss_vrl:*
28: gb_gss1:*
29: gb_gss2:*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	18.2	79.1	123	28	AQ848512 LMAJFV1_1
C 2	18.2	79.1	177	10	AW860790 QVO-CT038
C 3	17.8	77.4	183	10	AW859579 MRI-CT035
4	17.8	77.4	185	10	AW945878 QV4-EN004

5	17.2	74.8	128	12	BM417615
C 6	16.6	72.2	142	29	TA259E01Q
C 7	16.4	71.3	98	9	AW638838
C 8	16.2	70.4	105	9	AA932716
C 9	16.2	70.4	106	9	AA177143
C 10	16.2	70.4	106	12	BM751182
C 11	16.2	70.4	109	12	BM836523
C 12	16.2	70.4	111	9	AW238289
C 13	16.2	70.4	116	10	AW868506
C 14	16.2	70.4	116	10	AW868508
C 15	16.2	70.4	120	10	BE089629
C 16	16.2	70.4	120	10	BE709187
C 17	16.2	70.4	122	10	BE164153
C 18	16.2	70.4	128	9	AW265751
C 19	16.2	70.4	128	10	BE084274
C 20	16.2	70.4	130	10	BE708946
C 21	16.2	70.4	134	10	BE079661
C 22	16.2	70.4	134	10	BE079663
C 23	16.2	70.4	134	10	BE079796
C 24	16.2	70.4	134	10	BE093348
C 25	16.2	70.4	154	10	BE816793
C 26	16.2	70.4	160	10	AW946380
C 27	16.2	70.4	164	12	BM7511469
C 28	16.2	70.4	165	9	AI702380
C 29	16.2	70.4	165	9	AW805075
C 30	16.2	70.4	167	10	AW996105
C 31	16.2	70.4	167	10	BE828247
C 32	16.2	70.4	168	10	BE161974
C 33	16.2	70.4	169	9	AA194588
C 34	16.2	70.4	169	9	AA216249
C 35	16.2	70.4	169	10	AW996027
C 36	16.2	70.4	169	10	BE816807
C 37	16.2	70.4	170	9	AA094523
C 38	16.2	70.4	172	10	BG231090
C 39	16.2	70.4	173	14	T24894
C 40	16.2	70.4	173	14	EST469
C 41	16.2	70.4	174	10	BE816808
C 42	16.2	70.4	176	10	BE093337
C 43	16.2	70.4	177	9	AA247416
C 44	16.2	70.4	178	10	BE816768
45	16.2	70.4	179	10	AW897877

#### ALIGNMENTS

RESULT 1  
AQ848512 123 bp DNA linear GSS 25-MAY-2001  
LOCUS LMAJFV1\_lm10b07.xl Leishmania major FV1 random genomic library  
DEFINITION Leishmania major genomic clone LMAJFV1\_lm10b07\_3, similar to  
contains Alu repetitive element; contains 2.68 LHR-TAS-A.1  
leishmania repetitive element ; genomic survey sequence.

ACCESSION AQ848512  
VERSION AQ848512.1 GI:6053160

KEYWORDS GSS.

SOURCE Leishmania major

ORGANISM Leishmania major

Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae;

Leishmania.

REFERENCE 1 (bases 1 to 123)

Akopyants, N.S., Clifton, S.W., Martin, J., Pape, D., Wylie, T., Li, L.,

Kissinger, J.C., Roos, D.S. and Beverley, S.M.

A survey of the Leishmania major Friedlin strain V1 genome by

shotgun sequencing: a resource for DNA microarrays and expression

profiling

Mol. Biochem. Parasitol. 113 (2), 337-340 (2001)

JOURNAL MEDLINE

21192569

PUBMED 11295190

COMMENT Other GSSs: lm10b07.y1

Contact: Akopyants, NS / Beverley, SM

WashU Leishmania Project

Washington University School of Medicine



BASE COUNT		43 a	29 c	51 g	62 t	profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."	
ORIGIN							
Query Match		77.4%	Score 17.8;	DB 10;	Length 185;		
Best Local Similarity		76.2%	Pred. No. 7.5e+02;				
Matches		16;	Conservative	3;	Mismatches	2;	Indels 0; Gaps 0;
Qy	1	GTACTGCTCAGAGUAGGGUU 21					
Db	58	GTACTGCTCGGAGGTAGCGTT 78					
RESULT 5							
BM417615							
LOCUS							
DEFINITION		952020B09.y1 952 - BMS tissue from Walbot Lab (reduced rRNA) Zea mays cDNA, mRNA sequence.					
ACCESSION		BM417615					
VERSION		BM417615.1 GI:18384416					
KEYWORDS		EST.					
SOURCE		Zea mays					
ORGANISM		Zea mays					
REFERENCE		Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD clade; Panicoideae; Andropogoneae; Zea.					
AUTHORS		1 (bases 1 to 128)					
TITLE		Walbot, V.					
JOURNAL		Maize ESTs from various cDNA libraries sequenced at Stanford University					
COMMENT		Unpublished					
		Contact: Walbot V					
		Department of Biological Sciences					
		Stanford University					
		855 California Ave, Palo Alto, CA 94304, USA					
		Tel: 650 723 2327					
		Fax: 650 725 8221					
		Email: walbot@stanford.edu					
		Plate: 952020 row: B column: 09.					
FEATURES		Location/Qualifiers					
source		1..128					
		/organism="Zea mays"					
		/mol_type="mRNA"					
		/cultivar="BMS (Black Mexican Sweet)"					
		/db_xref="taxon:4577"					
		/tissue_type="suspension culture"					
		/dev_stage="mixed logarithmic and stationary growth phases"					
		/lab_host="DH10B"					
		/clone_lib="952 - BMS tissue from Walbot Lab (reduced rRNA)"					
		/notes="Vector: pUC19; Site_1: EcoRI; Site_2: EcoRI; The library was prepared by George Rudenko using poly (A) selected RNA and Universal Riboclone cDNA Synthesis System (Promega). cDNA was synthesized using both random and oligo(dT) primers in separate reactions and equipped with EcoRI adaptors. Library was size-fractionated on agarose gels (for insert size >400bp) and non-directionally cloned into EcoRI-digested pUC19 vector. Blue/white selection on carbenicillin-containing plates was used to recover positive clones."					
BASE COUNT		36 a	23 c	28 g	41 t		
ORIGIN							
Query Match		74.8%	Score 17.2;	DB 12;	Length 128;		
Best Local Similarity		68.2%	Pred. No. 1.2e+03;				
Matches		15;	Conservative	4;	Mismatches	3;	Indels 0; Gaps 0;
Qy	1	GTACTGCTCAGAGUAGGGUU 22					
Db	9	GTGAACCTCAGAGTAGGGTTA 30					



**TITLE** National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
**JOURNAL** Tumor Gene Index  
**COMMENT** Unpublished  
 Contact: Robert Strausberg, Ph.D.  
 Email: cgapbs-remail.nih.gov  
 Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.  
 CGAP Library Preparation: M. Bento Soares, Ph.D.  
 CGAP Library Arrayed by: Greg Lennon, Ph.D.  
 DNA Sequencing by: Washington University Genome Sequencing Center  
 Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html  
 Seq primer: -40m13 fwd. Et from Amersham  
 High quality sequence stop: 80.

**FEATURES**  
 source  
 1. .105  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /clone="IMAGE:1568653"  
 /tissue\_type="carcinoid"  
 /lab\_host="DH10B"  
 /clone\_lib="NCI CGAP Lu5"  
 /note="Organ: lung; Vector: pT73D-Pac (Pharmacia) with a modified polylinker; 1st strand cDNA was prepared from neuroendocrine lung carcinoid, and was then primed with a Not I - oligo(dT) primer. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT73 vector. Library is normalized. Library was constructed by Bento Soares and M. Fatima Bonaudo."

**BASE COUNT**  
 19 a 20 c 30 g 36 t

**Query Match** 70.4%; Score 16.2; DB 9; Length 105;  
**Best Local Similarity** 71.4%; Pred. No. 3.1e+03;  
**Matches** 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

**Qy** 1 GTACTGCTCAGAGUAGGGUU 21  
 ||||| : : : : :  
**Db** 36 GTACTGCTCGAGGTGGTT 56

**RESULT 9**  
**AA177143/c**  
**LOCUS** AA177143 106 bp mRNA linear EST 26-AUG-1998  
**DEFINITION** nc02b07.s1 NCI CGAP\_Pr3 Homo sapiens CDNA clone IMAGE:211, mRNA sequence.  
**ACCESSION** AA177143  
**VERSION** AA177143.1 GI:1758301  
**KEYWORDS** EST.  
**SOURCE** Homo sapiens (human)  
**ORGANISM** Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 1 (bases 1 to 106)  
**REFERENCE** NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.  
**AUTHORS** National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
**TITLE** Tumor Gene Index  
**JOURNAL** Unpublished  
**COMMENT** Contact: Robert Strausberg, Ph.D.  
 Email: cgapbs-remail.nih.gov  
 Tissue Procurement: W. Markston Linehan, M.D., Rodrigo Chuaqui, M.D., Michael Emmert-Buck, M.D., Ph.D.  
 CGAP Library Preparation: David B. Krizman, Ph.D.  
 DNA Sequencing by: Washington University Genome Sequencing Center  
 Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html  
 Seq primer: -40M13 fwd. from Amersham  
 High quality sequence stop: 76.

**FEATURES**  
 source  
 1. .106  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="ATCC (inhost):1363284"  
 /db\_xref="taxon:9606"  
 /clone="IMAGE:211"  
 /sex="Male"  
 /dev\_stage="45 years old"  
 /lab\_host="DH10B"  
 /clone\_lib="NCI CGAP Pr3"  
 /note="Vector: PAMP10; Site 1: NotI; Site 2: EcoRI; 1st strand cDNA was primed with oligo(dT)17 on 50 ng of DNase-treated, total cellular RNA obtained from 5,000-10,000 microdissected cells histologically-determined to be fully malignant prostate cancer cells. Double-stranded cDNA was ligated to EcoRI adaptors, 5 cycles of PCR applied to the cDNA with an adaptor-specific primer, and the resulting PCR product subcloned into pAMP10 by the UDG-cloning method (Life Technologies). Average insert size is 600 bp. NOTE: Not directionally cloned. This library was constructed by David Krizman."

**BASE COUNT**  
 34 a 33 c 21 g 17 t

**Query Match** 70.4%; Score 16.2; DB 9; Length 106;  
**Best Local Similarity** 71.4%; Pred. No. 3.1e+03;  
**Matches** 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

**Qy** 1 GTACTGCTCAGAGUAGGGUU 21  
 ||||| : : : : :  
**Db** 96 GTACTGCTCGAGGTGGTT 76

**RESULT 10**  
**BM751182/c**  
**LOCUS** BM751182 106 bp mRNA linear EST 04-MAR-2002  
**DEFINITION** K-EEST0027207 S9SNU601 Homo sapiens CDNA clone S9SNU601-11-D05 5', mRNA sequence.  
**ACCESSION** BM751182  
**VERSION** BM751182.1 GI:19080800  
**KEYWORDS** EST.  
**SOURCE** Homo sapiens (human)  
**ORGANISM** Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 1 (bases 1 to 106)  
**REFERENCE** Kim, N.S., Hahn, Y., Oh, J.H., Lee, J.Y., Ahn, H.Y., Chu, M.Y., Kim, M.R., Oh, K.J., Cheong, J.E., Sohn, H.Y., Kim, J.M., Park, H.S., Kim, S. and Kim, Y.S.  
**AUTHORS** 21C Frontier Korean EST Project 2001  
**TITLE** Unpublished  
**JOURNAL** Contact: Kim YS  
**COMMENT** Genome Research Center  
 Korea Research Institute of Bioscience & Biotechnology  
 52 Eoeun-dong Yuseong-gu, Daejeon 305-333, South Korea  
 Tel: +82-42-860-4470  
 Fax: +82-42-860-4409  
 Email: yongsung@mail.kribb.re.kr  
 Plate: 11 row: D column: 05  
 High quality sequence stop: 106.

**FEATURES**  
 source  
 1. .106  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /clone="S9SNU601-11-D05"  
 /sex="M"  
 /tissue\_type="Ascites"  
 /cell\_type="Epithelial"  
 /cell\_line="SNU-601"  
 /lab\_host="Top10F"  
 /clone\_lib="S9SNU601"



/note="Organ: Stomach; Vector: pME18-FL3; Site 1: XhoI; Site 2: XhoI; The poly (A)+ RNA was dephosphorylated with bacterial alkaline phosphatase (BAP) and then decapped with tabacco acid pyrophosphatase (TAP). The decapped intact mRNA was ligated with DNA-RNA linker including SfiI site by treatment of T4 RNA ligase and the first strand cDNA was synthesized with Superscript II using SfiI oligo-dT primer. After first strand synthesis, RNA was degraded by NaOH treatment and cDNA was amplified by PCR reaction. The PCR products were digested with SfiI and cloned into DraIII- digested pME18S-FL3 vector. The obtained cDNA vectors were used for transformation of competent cells E. coli Top10F' by electroporation method. The cDNA libraries constructed by this method are full-length enriched cDNA library."

BASE COUNT 36 a 31 c 20 g 19 t  
ORIGIN

Query Match 70.4%; Score 16.2; DB 12; Length 106;  
Best Local Similarity 71.4%; Pred. No. 3.1e+03;  
Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTACTGCTCAGAGGUAGGGUU 21  
||||| : : : : :  
Db 70 GTACTGCTCGAGGTTGGGTT 50

RESULT 11  
BM836523/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

BM836523 109 bp mRNA linear EST 06-MAR-2002  
K-EST0112212 S9SNU601 Homo sapiens cDNA clone S9SNU601-63-E06 5',  
mRNA sequence.

BM836523 1 GI:19192932  
EST.  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 109)  
Kim,N.S., Hahn,Y., Oh,J.H., Lee,J.Y., Ahn,H.Y., Chu,M.Y., Kim,M.R.,  
Oh,K.J., Cheong,J.E., Sohn,H.Y., Kim,J.M., Park,H.S., Kim,S. and  
Kim,Y.S.

TITLE 21C Frontier Korean EST Project 2001

JOURNAL  
COMMENT  
Contact: Kim YS  
Genome Research Center  
Korea Research Institute of Bioscience & Biotechnology  
52 Eoeun-dong Yuseong-gu, Daejeon 305-333, South Korea  
Tel: +82-42-860-4470  
Fax: +82-42-860-4409  
Email: yongsung@mail.kribb.re.kr  
Plate: 63 row: E column: 06  
High quality sequence stop: 109.  
Location/Qualifiers

FEATURES  
source  
1. .109  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="S9SNU601-63-E06"  
/sex="M"  
/tissue\_type="Ascites"  
/cell\_type="Epithelial"  
/cell\_line="SNU-601"  
/lab\_host="Top10F"  
/clone\_lib="S9SNU601"  
/note="Organ: Stomach; Vector: pME18-FL3; Site 1: XhoI; Site 2: XhoI; The poly (A)+ RNA was dephosphorylated with bacterial alkaline phosphatase (BAP) and then decapped with tabacco acid pyrophosphatase (TAP). The decapped intact mRNA was ligated with DNA-RNA linker including SfiI site by treatment of T4 RNA ligase and the first strand cDNA was synthesized with Superscript II using SfiI

oligo-dT primer. After first strand synthesis, RNA was degraded by NaOH treatment and cDNA was amplified by PCR reaction. The PCR products were digested with SfiI and cloned into DraIII- digested pME18S-FL3 vector. The obtained cDNA vectors were used for transformation of competent cells E. coli Top10F' by electroporation method. The cDNA libraries constructed by this method are full-length enriched cDNA library."

BASE COUNT 38 a 35 c 17 g 19 t  
ORIGIN

Query Match 70.4%; Score 16.2; DB 12; Length 109;  
Best Local Similarity 71.4%; Pred. No. 3.2e+03;  
Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTACTGCTCAGAGGUAGGGUU 21  
||||| : : : : :  
Db 32 GTACTGCTCGAGGTTGGGTT 12

RESULT 12  
AW238289  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

AW238289 111 bp mRNA linear EST 13-DEC-1999  
XP20d02.x1 NCI\_CGAP\_HN10 Homo sapiens cDNA clone IMAGE:2740899 3',  
mRNA sequence.

AW238289 1 GI:6570606  
EST.  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 111)  
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.  
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
Tumor Gene Index  
Unpublished

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT  
Contact: Robert Strausberg, Ph.D.  
Email: cgapbs-r@mail.nih.gov  
Tissue Procurement: Edward Shillitoe Ph.D., Silvio Gutkind Ph.D.,  
Chidchanok Leethanakul D.D.S., Michael Emmert-Buck M.D. Ph.D.  
CDNA Library Preparation: David B. Krizman, Ph.D.  
CDNA Library Arrayed by: Greg Lennon, Ph.D.  
DNA Sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
www-bio.llnl.gov/bbrp/image/image.html

Possible reversed clone: polyT not found  
Seq primer: -400P from Gibco  
High quality sequence stop: 104.  
Location/Qualifiers

FEATURES  
source  
1. .111  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:2740899"  
/tissue\_type="carcinoma in situ from retromolar trigone"  
/lab\_host="DH10B"  
/clone\_lib="NCI CGAP HN10"  
/note="Vector: pAMP10; cDNA made by oligo-dT priming. Non-directionally cloned into the UDG sites of pAMP10. Size-selected on agarose gel, average insert size 500 bp. Primary library; non-amplified. cDNA Library Preparation: David B. Krizman, Ph.D (NCI). Reference: Krizman et al. (1996) Cancer Research 56:5380-5383."

BASE COUNT 19 a 20 c 33 g 39 t  
ORIGIN

Query Match 70.4%; Score 16.2; DB 9; Length 111;  
Best Local Similarity 71.4%; Pred. No. 3.2e+03;  
Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1 GTACTGCTCAGUAGGUU 21  
||||||| : |||:  
Db 80 GTACTGCTCGAGGTGGTT 100

## RESULT 13

AW868506/c 116 bp mRNA linear EST 22-MAY-2000  
LOCUS MRI-SN0063-040500-001-a03\_1 SN0063 Homo sapiens cDNA, mRNA

## DEFINITION

sequence.

## ACCESSION

AW868506

## VERSION

AW868506.1 GI:8002545

## KEYWORDS

EST.

## SOURCE

Homo sapiens (human)

## ORGANISM

Homo sapiens

## REFERENCE

1 (bases 1 to 116)

## AUTHORS

Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R., Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F., Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H., Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and Simpson,A.J.

## TITLE

Shotgun sequencing of the human transcriptome with ORF expressed

## JOURNAL

Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)

## MEDLINE

20202663

## PUBMED

10737800

## COMMENT

Contact: Simpson A.J.G.

Laboratory of Cancer Genetics

Ludwig Institute for Cancer Research

Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP, Brazil

Tel: +55-11-2704922

Fax: +55-11-2707001

Email: asimpson@ludwig.org.br

This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL

(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=st2-MR1-SN0063-040

500-001-a03.1&t3=2000-05-04&t4=1)

Seq primer: puc 18 forward

High quality sequence stop: 116.

## FEATURES

Location/Qualifiers

1..116

/organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="taxon:9606"

/dev\_stage="Adult"

/clone\_lib="SN0063"

/note="Organ: stomach normal; Vector: puc18; Site 1: SmaI; Site 2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."

37 a 36 c 22 g 21 t

## BASE COUNT

ORIGIN

Query Match 70.4%; Score 16.2; DB 10; Length 116;

Best Local Similarity 71.4%; Pred. NO. 3.3e+03;

Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

## Qy

1 GTACTGCTCAGUAGGUU 21

||||||| : |||:

## Db

83 GTACTGCTCGAGGTGGTT 63

## RESULT 14

AW868508/c 116 bp mRNA linear EST 22-MAY-2000

## LOCUS

DEFINITION MRI-SN0063-040500-001-b03\_1 SN0063 Homo sapiens cDNA, mRNA

## ACCESSION

AW868508

## VERSION

AW868508.1 GI:8002547

## KEYWORDS

EST.

## SOURCE

Homo sapiens (human)

## ORGANISM

Homo sapiens

## REFERENCE

1 (bases 1 to 116)

## AUTHORS

Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R., Nagai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F., Goldman,G.H., Carvalho,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H., Brunstein,A., deOliveira,P.S., Bucher,P., Jongeneel,C.V., O'Hare,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and Simpson,A.J.

## TITLE

Shotgun sequencing of the human transcriptome with ORF expressed

## JOURNAL

Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)

## MEDLINE

20202663

## PUBMED

10737800

## COMMENT

Contact: Simpson A.J.G.

Laboratory of Cancer Genetics

Ludwig Institute for Cancer Research

Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP, Brazil

Tel: +55-11-2704922

Fax: +55-11-2707001

Email: asimpson@ludwig.org.br

This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL

(http://www.ludwig.org.br/scripts/gethtml2.pl?tl=st2-MR1-SN0063-040

500-001-b03.1&t3=2000-05-04&t4=1)

Seq primer: puc 18 forward

High quality sequence stop: 116.

## FEATURES

Location/Qualifiers

1..116

/organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="taxon:9606"

/dev\_stage="Adult"

/clone\_lib="SN0063"

/note="Organ: stomach normal; Vector: puc18; Site 1: SmaI; Site 2: SmaI; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions."

37 a 36 c 22 g 21 t

## BASE COUNT

ORIGIN

Query Match 70.4%; Score 16.2; DB 10; Length 116;

Best Local Similarity 71.4%; Pred. NO. 3.3e+03;

Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

## Qy

1 GTACTGCTCAGUAGGUU 21

||||||| : |||:

## Db

83 GTACTGCTCGAGGTGGTT 63

## RESULT 15

BE089629

## LOCUS

DEFINITION QV0-BT0703-120500-225-e10 BT0703 Homo sapiens cDNA, mRNA sequence.

## ACCESSION

BE089629

## VERSION

BE089629.1 GI:8480047

## KEYWORDS

EST.

## SOURCE

Homo sapiens (human)

## ORGANISM

Homo sapiens

## REFERENCE

1 (bases 1 to 120)

## AUTHORS

Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,

Nagai, M.A., da Silva, W. Jr., Zago, M.A., Bordin, S., Costa, F.F.,  
Goldman, G.H., Carvalho, A.F., Matsukuma, A., Baia, G.S., Simpson, D.H.,  
Brunstein, A., de Oliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare,  
M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.J. and  
Simpson, A.J.

Shotgun sequencing of the human transcriptome with ORF expressed  
sequence tags

Proc Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)

20202663

10737800

## COMMENT

Contact: Simpson A.J.G.

Laboratory of Cancer Genetics

Ludwig Institute for Cancer Research

Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,

Brazil

Tel: +55-11-2704922

Fax: +55-11-2707001

Email: asimpson@ludwig.org.br

This sequence was derived from the FAPESP/LICR Human Cancer Genome

Project. This entry can be seen in the following URL

(<http://www.ludwig.org.br/scripts/gethtml2.pl?tl=&t2=QV0-BT0703-120>)

500-225-el0&t3=2000-05-12&t4=1)

Seq primer: puc 18 forward

High quality sequence start: 13

High quality sequence stop: 120.

## FEATURES

source

1..120

/organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="taxon:9606"

/dev\_stage="Adult"

/clone\_lib="BT0703"

/notes="Organ: breast; Vector: puc18; Site\_1: SmaI; Site\_2:

SmaI; A mini-library was made by cloning products derived

from ORSTES PCR (U.S. Letters Patent application No. 196

,716 - Ludwig Institute for Cancer Research) profiles

into the pUC 18 vector. Reverse transcription of tissue

mRNA and cDNA amplification were performed under low

stringency conditions."

23 a 27 c 32 g 38 t

BASE COUNT

ORIGIN

Query Match

Best Local Similarity 70.4%; Score 16.2; DB 10; Length 120;

Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTACTGCTCAGAGUAGGUU 21

||||| : |||:

Db 67 GTACTGCTCGAGGTTGGGT 87

Search completed: November 8, 2003, 05:49:03

Job time : 1616 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2003 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 8, 2003, 04:09:27 ; Search time 1533 Seconds  
(without alignments)  
613.778 Million cell updates/sec

Title: US-09-817-387-16

Perfect score: 23

Sequence: 1 gtactgctcagaguuagguag 23

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 1812986

Minimum DB seq length: 0

Maximum DB seq length: 200

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl :

1: gb\_ba :

2: gb\_htg :

3: gb\_in :

4: gb\_om :

5: gb\_ov :

6: gb\_pat :

7: gb\_ph :

8: gb\_pl :

9: gb\_pr :

10: gb\_ro :

11: gb\_sts :

12: gb\_sy :

13: gb\_un :

14: gb\_vi :

15: em\_ba :

16: em\_fun :

17: em\_hum :

18: em\_in :

19: em\_mu :

20: em\_om :

21: em\_or :

22: em\_ov :

23: em\_pat :

24: em\_ph :

25: em\_pl :

26: em\_ro :

27: em\_sts :

28: em\_un :

29: em\_vi :

30: em\_htg\_hum :

31: em\_htg\_inv :

32: em\_htg\_other :

33: em\_htg\_mus :

34: em\_htg\_pln :

35: em\_htg\_rod :

36: em\_htg\_mam :

37: em\_htg\_vrt :

38: em\_sy :

39: em\_htgo\_hum :

40: em\_htgo\_mus :

41: em\_htgo\_other :

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Description
1	21.4	93.0	35	6	BD084922	BD084922 Chimeric
2	19.8	86.1	31	6	BD084916	BD084916 Chimeric
3	18.8	81.7	31	6	BD084925	BD084925 Chimeric
4	18.2	79.1	31	6	BD084919	BD084919 Chimeric
C 5	18.2	79.1	160	3	AF031203	AF031203 Leishmani
C 6	16.2	70.4	174	9	HS22F7F	Z55760 H.sapiens C
C 7	16.2	70.4	182	9	HS27C11F	Z61706 H.sapiens C
C 8	16.2	70.4	190	9	HS169H8F	Z57252 H.sapiens C
C 9	15.8	68.7	118	5	GGA240706	AJ240706 Gallus ga
C 10	15.6	67.8	44	6	A79663	A79663 Sequence 12
C 11	15.6	67.8	44	6	AR147337	AR147337 Sequence
C 12	15.6	67.8	196	5	AF427996	AF427996 Fringilla
C 13	15.4	67.0	25	6	BD084917	BD084917 Chimeric
C 14	15.4	67.0	25	6	BD084920	BD084920 Chimeric
C 15	15.2	66.1	145	6	BD049748	BD049748 Sequence
C 16	15.2	66.1	176	5	AF427997	AF427997 Fringilla
C 17	15	65.2	18	6	A79665	A79665 Sequence 14
C 18	15	65.2	18	6	AR147339	AR147339 Sequence
C 19	15	65.2	21	6	AR037852	AR037852 Sequence
C 20	15	65.2	21	6	AR069385	AR069385 Sequence
C 21	15	65.2	21	6	AR087788	AR087788 Sequence
C 22	15	65.2	21	6	AR211028	AR211028 Sequence
C 23	15	65.2	29	6	AR257904	AR257904 Sequence
C 24	15	65.2	29	6	AR257905	AR257905 Sequence
C 25	15	65.2	29	6	AR257906	AR257906 Sequence
C 26	15	65.2	29	6	AR257907	AR257907 Sequence
C 27	15	65.2	29	6	E15450	E15450 Oligonucleo
C 28	15	65.2	29	6	E40924	E40924 Method for
C 29	15	65.2	34	6	AR257913	AR257913 Sequence
C 30	15	65.2	38	6	AR307306	AR307306 Sequence
C 31	15	65.2	51	6	AX117809	AX117809 Sequence
C 32	15	65.2	62	6	AR037864	AR037864 Sequence
C 33	15	65.2	62	6	AR054745	AR054745 Sequence
C 34	15	65.2	62	6	AR069397	AR069397 Sequence
C 35	15	65.2	62	6	AR243525	AR243525 Sequence
C 36	15	65.2	62	6	AX395632	AX395632 Sequence
C 37	15	65.2	62	6	BD011314	BD011314 Human tel
C 38	15	65.2	62	6	E37063	E37063 Human telom
C 39	15	65.2	68	6	AX395585	AX395585 Sequence
C 40	15	65.2	76	6	A60813	A60813 Sequence 12
C 41	15	65.2	125	10	MMU403205	AJ403205 M.musculu
C 42	15	65.2	128	5	GGA240711	AJ240711 Gallus ga
C 43	15	65.2	135	5	GGA240728	AJ240728 Gallus ga
C 44	15	65.2	145	5	GGA240732	AJ240732 Gallus ga
C 45	15	65.2	148	5	GGA240702	AJ240702 Gallus ga

ALIGNMENTS

RESULT 1	BD084922	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
LOCUS	BD084922	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
DEFINITION	BD084922	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
ACCESSION	BD084922	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
VERSION	BD084922.1	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
KEYWORDS	JP 2001524972-A/7	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
SOURCE	JP 2001524972-A/7	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
ORGANISM	JP 2001524972-A/7	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
REFERENCE	1	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
AUTHORS	Matthes, E. and Lipinski, M.V.J.	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
TITLE	Chimeric oligonucleotides and the use thereof	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
JOURNAL	Patent: JP 2001524972-A 7 04-DEC-2001	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002
	MAX DELBRUCK CENTRUM FUR MOLEKULARE MEDIZIN	Chimeric	35 bp	DNA	linear	PAT 27-AUG-2002

COMMENT OS Artificial Sequence  
 PN JP 2001524972-A/7  
 PD 04-DEC-2001  
 PF 04-MAY-1998 JP 1998547618  
 PR 02-MAY-1997 DE 197 20 151.2  
 PI ECKART MATTHES,MARTIN VON JANTA LIPINSKI  
 PC C07H21/00  
 CC Description of Artificial Sequence:chimera oligonucleotide FH  
 Key source Location/Qualifiers  
 1. .35  
 /organism='Artificial Sequence'.  
 FT  
 FT Location/Qualifiers  
 1. .35  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 BASE COUNT 11 a 5 c 10 g 9 t  
 ORIGIN  
 Query Match 93.0%; Score 21.4; DB 6; Length 35;  
 Best Local Similarity 78.3%; Pred. No. 2.8;  
 Matches 18; Conservative 4; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 GTACTGCTCAGAGUAGGUAG 23  
 |||||  
 DB 9 GGACTGCTCAGAGTAGGTTAG 31  
 RESULT 2  
 BD084916  
 LOCUS Chimeric oligonucleotides and the use thereof. 31 bp DNA linear PAT 27-AUG-2002  
 DEFINITION  
 ACCESSION BD084916  
 VERSION BD084916.1 GI:22630526  
 KEYWORDS JP 2001524972-A/1.  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 REFERENCE 1 (bases 1 to 31)  
 AUTHORS Matthes,E. and Lipinski,M.V.J.  
 TITLE Chimeric oligonucleotides and the use thereof  
 JOURNAL Patent: JP 2001524972-A 1 04-DEC-2001;  
 MAX DELBRUCK CENTRUM FUR MOLEKULARE MEDIZIN  
 OS Artificial Sequence  
 PN JP 2001524972-A/1  
 PD 04-DEC-2001  
 PF 04-MAY-1998 JP 1998547618  
 PR 02-MAY-1997 DE 197 20 151.2  
 PI ECKART MATTHES,MARTIN VON JANTA LIPINSKI  
 PC C07H21/00  
 CC Description of Artificial Sequence:chimera oligonucleotide FH  
 Key source Location/Qualifiers  
 1. .31  
 /organism='Artificial Sequence'.  
 FT  
 FT Location/Qualifiers  
 1. .31  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 BASE COUNT 8 a 4 c 9 g 10 t  
 ORIGIN  
 Query Match 86.1%; Score 19.8; DB 6; Length 31;  
 Best Local Similarity 73.9%; Pred. No. 21;  
 Matches 17; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 GTACTGCTCAGAGUAGGUAG 23  
 |||||  
 DB 9 GTACTGCTCAGAGTAGGTTAG 31  
 RESULT 3  
 BD084925

LOCUS BD084925 31 bp DNA linear PAT 27-AUG-2002  
 DEFINITION Chimeric oligonucleotides and the use thereof.  
 ACCESSION BD084925  
 VERSION BD084925.1 GI:22630535  
 KEYWORDS JP 2001524972-A/10.  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 REFERENCE 1 (bases 1 to 31)  
 AUTHORS Matthes,E. and Lipinski,M.V.J.  
 TITLE Chimeric oligonucleotides and the use thereof  
 JOURNAL Patent: JP 2001524972-A 10 04-DEC-2001;  
 MAX DELBRUCK CENTRUM FUR MOLEKULARE MEDIZIN  
 OS Artificial Sequence  
 PN JP 2001524972-A/10  
 PD 04-DEC-2001  
 PF 04-MAY-1998 JP 1998547618  
 PR 02-MAY-1997 DE 197 20 151.2  
 PI ECKART MATTHES,MARTIN VON JANTA LIPINSKI  
 PC C07H21/00  
 CC Description of Artificial Sequence:chimera oligonucleotide CC  
 n represents 3' azidodeoxyguanosin  
 FH Key Location/Qualifiers  
 1. .31  
 /organism='Artificial Sequence'.  
 FT  
 FT Location/Qualifiers  
 1. .31  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"  
 BASE COUNT 8 a 4 c 8 g 10 t 1 others  
 ORIGIN  
 Query Match 81.7%; Score 18.8; DB 6; Length 31;  
 Best Local Similarity 72.7%; Pred. No. 74;  
 Matches 16; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 GTACTGCTCAGAGUAGGUUA 22  
 |||||  
 DB 9 GTACTGCTCAGAGTAGGTTA 30  
 RESULT 4  
 BD084919  
 LOCUS Chimeric oligonucleotides and the use thereof. 31 bp DNA linear PAT 27-AUG-2002  
 DEFINITION  
 ACCESSION BD084919  
 VERSION BD084919.1 GI:22630529  
 KEYWORDS JP 2001524972-A/4.  
 SOURCE synthetic construct  
 ORGANISM artificial sequences.  
 REFERENCE 1 (bases 1 to 31)  
 AUTHORS Matthes,E. and Lipinski,M.V.J.  
 TITLE Chimeric oligonucleotides and the use thereof  
 JOURNAL Patent: JP 2001524972-A 4 04-DEC-2001;  
 MAX DELBRUCK CENTRUM FUR MOLEKULARE MEDIZIN  
 OS Artificial Sequence  
 PN JP 2001524972-A/4  
 PD 04-DEC-2001  
 PF 04-MAY-1998 JP 1998547618  
 PR 02-MAY-1997 DE 197 20 151.2  
 PI ECKART MATTHES,MARTIN VON JANTA LIPINSKI  
 PC C07H21/00  
 CC Description of Artificial Sequence:chimera oligonucleotide FH  
 Key source Location/Qualifiers  
 1. .31  
 /organism='Artificial Sequence'.  
 FT  
 FT Location/Qualifiers  
 1. .31  
 /organism="synthetic construct"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32630"

```

BASE COUNT      9 a      4 c      8 g      10 t
ORIGIN
Query Match
Best Local Similarity 79.1%; Score 18.2; DB 6; Length 31;
Matches 16; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTACTGCTCAGAGUAGGUUAG 23
||||| ||||| ||||| ||||| |||||
Db 9 GTACTGCTCAGAGTTAGGTTAG 31

RESULT 5
AF031203/c
LOCUS      160 bp      DNA      linear      INV 20-MAY-1998
DEFINITION Leishmania major strain 1503 telomere-associated sequence, clone
            major7.
ACCESSION  AF031203
VERSION     AF031203.1 GI:3142346
KEYWORDS   Leishmania major
SOURCE     Leishmania major
ORGANISM   Leishmania major
            Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae;
            Leishmania.
REFERENCE  1 (bases 1 to 160)
AUTHORS   Fu, G. and Barker, D.C.
TITLE     Characterisation of Leishmania telomeres reveals unusual telomeric
            repeats and conserved telomere-associated sequence
JOURNAL   Nucleic Acids Res. 26 (9), 2161-2167 (1998)
MEDLINE   98213745
PUBMED    9547275
REFERENCE  2 (bases 1 to 160)
AUTHORS   Fu, G. and Barker, D.C.
TITLE     Direct Submission
JOURNAL   Submitted (24-OCT-1997) Department of Pathology, University of
            Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK
FEATURES   Location/Qualifiers
            source
            1..160
                /organism="Leishmania major"
                /mol_type="genomic DNA"
                /strain="1503"
                /db_xref="taxon:5664"
                /clone="major7"
            misc_feature
            1..129
                /note="telomere-associated sequence"
BASE COUNT  49 a      54 c      30 g      27 t
ORIGIN
Query Match
Best Local Similarity 79.1%; Score 18.2; DB 3; Length 160;
Matches 16; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTACTGCTCAGAGUAGGUUAG 23
||||| ||||| ||||| ||||| |||||
Db 31 GTACTGCTCAGAGTTAGGTTAG 9

RESULT 6
HS62F7F/c
LOCUS      174 bp      DNA      linear      PRI 17-OCT-1995
DEFINITION H.sapiens CpG island DNA genomic MseI fragment, clone 62f7, forward
            read cp962f7.ft1a.
ACCESSION  Z55760
VERSION     Z55760.1 GI:1021801
KEYWORDS   CpG island; genomic MseI fragment.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Cross, S.H., Charlton, J.A., Nan, X. and Bird, A.P.
TITLE     Purification of CpG islands using a methylated DNA binding column
JOURNAL   Nat. Genet. 6 (3), 236-244 (1994)
MEDLINE   94282070
PUBMED    8012384
REFERENCE  2 (bases 1 to 182)
AUTHORS   MacDonald, M., Huckle, E., Wilkinson, P. and Micklem, G.
TITLE     Direct Submission
JOURNAL   Submitted (16-OCT-1995) The Sanger Centre, Hinxton, Cambridgeshire,
            CB10 1RQ, England. E-mail contact: humquery@sanger.ac.uk
COMMENT    Clones are available from the UK MRC Human Genome Mapping Project
            Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
            http://www.hgmp.mrc.ac.uk/ for details
            or contact: biohelp@hgmp.mrc.ac.uk.
            Location/Qualifiers
            source
            1..182
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /clone="57c11"
                /sex="male"
                /tissue_type="blood"
                /clone_lib="CGI-1"
                /dev_stage="adult"
BASE COUNT  61 a      46 c      34 g      39 t      2 others

BASE COUNT      9 a      4 c      8 g      10 t
ORIGIN
Query Match
Best Local Similarity 70.4%; Score 16.2; DB 9; Length 174;
Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTACTGCTCAGAGUAGGUU 21
||||| ||||| ||||| ||||| |||||
Db 53 GTACTGCTCGAGGTGGGTT 33

RESULT 7
HS57C11F/c
LOCUS      182 bp      DNA      linear      PRI 22-OCT-1995
DEFINITION H.sapiens CpG island DNA genomic MseI fragment, clone 57c11,
            forward read cp957c11.ft1a.
ACCESSION  Z61706
VERSION     Z61706.1 GI:1034084
KEYWORDS   CpG island; genomic MseI fragment.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS   Cross, S.H., Charlton, J.A., Nan, X. and Bird, A.P.
TITLE     Purification of CpG islands using a methylated DNA binding column
JOURNAL   Nat. Genet. 6 (3), 236-244 (1994)
MEDLINE   94282070
PUBMED    8012384
REFERENCE  2 (bases 1 to 182)
AUTHORS   MacDonald, M., Huckle, E., Wilkinson, P. and Micklem, G.
TITLE     Direct Submission
JOURNAL   Submitted (16-OCT-1995) The Sanger Centre, Hinxton, Cambridgeshire,
            CB10 1RQ, England. E-mail contact: humquery@sanger.ac.uk
COMMENT    Clones are available from the UK MRC Human Genome Mapping Project
            Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:
            http://www.hgmp.mrc.ac.uk/ for details
            or contact: biohelp@hgmp.mrc.ac.uk.
            Location/Qualifiers
            source
            1..182
                /organism="Homo sapiens"
                /mol_type="genomic DNA"
                /db_xref="taxon:9606"
                /clone="57c11"
                /sex="male"
                /tissue_type="blood"
                /clone_lib="CGI-1"
                /dev_stage="adult"
BASE COUNT  61 a      46 c      34 g      39 t      2 others

```

## ORIGIN

Query Match 70.4%; Score 16.2; DB 9; Length 182;  
 Best Local Similarity 71.4%; Pred. No. 1.6e+03;  
 Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTACTGCTCAGAGUAGGUU 21  
 ||||| ||| : ||| :  
 Db 53 GTACTGCTCGAGGTTGGTT 33

## RESULT 8

HS169H8F/c  
 LOCUS 190 bp DNA linear PRI 18-OCT-1995  
 DEFINITION H. sapiens CpG island DNA genomic MseI fragment, clone 169h8,  
 forward read cpg169h8.ftla.  
 ACCESSION 257252  
 VERSION 1 GI:1028483  
 KEYWORDS CpG island; genomic MseI fragment.  
 SOURCE Homo sapiens (human)

## ORGANISM

ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

## REFERENCE

AUTHORS Cross, S.H., Charlton, J.A., Nan, X. and Bird, A.P.  
 TITLE Purification of CpG islands using a methylated DNA binding column  
 JOURNAL Nat. Genet. 6 (3), 236-244 (1994)  
 MEDLINE 94282070  
 PUBMED 8012384

## REFERENCE

2 (bases 1 to 190)  
 Dods, S.J., Huckle, E., Wilkinson, P. and Micklem, G.  
 Direct Submission  
 Submitted (16-OCT-1995) The Sanger Centre, Hinxton, Cambridgeshire,  
 CB10 1RQ, England. E-mail contact: humquery@sanger.ac.uk  
 Vector: pGEM-52f(-)  
 Clones are available from the UK MRC Human Genome Mapping Project  
 Resource Centre, Hinxton, Cambridgeshire CB10 1RQ, UK. See URL:  
 http://www.hgmp.mrc.ac.uk/ for details  
 or contact: biohelp@hgmp.mrc.ac.uk.

## FEATURES

source  
 1..190  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /clone="169h8"  
 /sex="male"  
 /tissue type="blood"  
 /clone\_lib="CGI-1"  
 /dev\_stage="adult"

BASE COUNT 61 a 50 c 37 g 40 t 2 others  
 ORIGIN

Query Match 70.4%; Score 16.2; DB 9; Length 190;  
 Best Local Similarity 71.4%; Pred. No. 1.6e+03;  
 Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 1 GTACTGCTCAGAGUAGGUU 21  
 ||||| ||| : ||| :  
 Db 53 GTACTGCTCGAGGTTGGTT 33

## RESULT 9

GGA240706  
 LOCUS 118 bp DNA linear VRT 05-APR-1999  
 DEFINITION Gallus gallus HD7/E2 telomere junction.  
 ACCESSION AJ240706

VERSION 1 GI:4583601  
 KEYWORDS Gallus gallus (chicken)

## SOURCE

ORGANISM Gallus gallus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Archosauria; Aves; Neognathae; Galliformes; Phasianidae;  
 Phasianinae; Gallus.

## REFERENCE

AUTHORS Thomson, P.A. and Burke, T.  
 TITLE The isolation of chicken telomere junction fragments  
 JOURNAL Unpublished

## REFERENCE

2 (bases 1 to 118)

## AUTHORS

Thomson, P.A.  
 Direct Submission  
 Submitted (02-MAR-1992) Thomson P.A., Department of Biology,  
 University of Leicester, University Road, Leicester, LE1 7RH,  
 UNITED KINGDOM

## FEATURES

source  
 Location/Qualifiers  
 1..118  
 /organism="Gallus gallus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9031"  
 /clone="HD7/E2"  
 /clone\_lib="anchored PCR library"

BASE COUNT 19 a 7 c 49 g 43 t  
 ORIGIN

Query Match 68.7%; Score 15.8; DB 5; Length 118;  
 Best Local Similarity 68.4%; Pred. No. 2.8e+03;  
 Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 5 TCCTCAGAGUAGGUUAG 23  
 ||||| ||| : ||| :  
 Db 99 TGCTTAGGTTAGGTTAG 117

## RESULT 10

A79663/c  
 LOCUS 44 bp DNA linear PAT 20-OCT-1999  
 DEFINITION Sequence 12 from Patent WO9720069.  
 ACCESSION A79663

VERSION A79663.1 GI:5092617

## KEYWORDS

unidentified

## SOURCE

unclassified.

## REFERENCE

1 (bases 1 to 44)  
 Emrich, T. and Leying, H.  
 METHOD OF DETECTING TELOMERASE ACTIVITY  
 Patent: WO 9720069-A 12 05-JUN-1997;  
 BOEHRINGER MANNHEIM GMBH (DE); EMRICH THOMAS (DE)

## FEATURES

source  
 1..44  
 /organism="unidentified"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:32644"

BASE COUNT 13 a 16 c 9 g 6 t  
 ORIGIN

Query Match 67.8%; Score 15.6; DB 6; Length 44;  
 Best Local Similarity 63.6%; Pred. No. 4e+03;  
 Matches 14; Conservative 4; Mismatches 4; Indels 0; Gaps 0;

QY 2 TACTGCTCAGAGUAGGUUAG 23  
 ||||| ||| : ||| :  
 Db 28 TTCTGTTAGGTTAGGTTAG 7

## RESULT 11

AR147337/c  
 LOCUS 44 bp DNA linear PAT 08-AUG-2001  
 DEFINITION Sequence 12 from patent US 6221584.  
 ACCESSION AR147337

VERSION AR147337.1 GI:15111140  
 KEYWORDS

## SOURCE

Unknown.

## ORGANISM

Unclassified.

## REFERENCE

1 (bases 1 to 44)  
 Emrich, T., Leying, H., Hinzpeter, M. and Karl, G.





Search completed: November 8, 2003, 05:21:59  
Job time : 1537 secs